| Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial MS Brose, B Robinson, SI Sherman, J Krajewska, CC Lin, F Vaisman, ... The Lancet Oncology 22 (8), 1126-1138, 2021 | 204 | 2021 |
| Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer G Serna, F Ruiz-Pace, J Hernando, L Alonso, R Fasani, S Landolfi, ... Annals of Oncology 31 (10), 1366-1375, 2020 | 103 | 2020 |
| Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509) J Capdevila, N Fazio, C Lopez, A Teulé, JW Valle, S Tafuto, A Custodio, ... Journal of Clinical Oncology 39 (20), 2304-2312, 2021 | 81 | 2021 |
| Early evolutionary divergence between papillary and anaplastic thyroid cancers J Capdevila, R Mayor, FM Mancuso, C Iglesias, G Caratù, I Matos, ... Annals of Oncology 29 (6), 1454-1460, 2018 | 60 | 2018 |
| Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study C Nesti, K Bräutigam, M Benavent, L Bernal, H Boharoon, J Botling, ... The lancet oncology 24 (2), 187-194, 2023 | 55 | 2023 |
| ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma H Verdaguer, T Saurí, DA Acosta, M Guardiola, A Sierra, J Hernando, ... Clinical Cancer Research 28 (8), 1662-1671, 2022 | 47 | 2022 |
| Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas J Capdevila, O Arqués, JR Hernández Mora, J Matito, G Caratù, ... Clinical Cancer Research 26 (4), 902-909, 2020 | 44 | 2020 |
| Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is≥ 10%? E Merola, T Alonso Gordoa, P Zhang, T Al‐Toubah, E Pellè, ... The Oncologist 26 (4), 294-301, 2021 | 34 | 2021 |
| Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study M Mitjavila, P Jimenez-Fonseca, P Belló, V Pubul, JC Percovich, ... European journal of nuclear medicine and molecular imaging 50 (8), 2486-2500, 2023 | 31 | 2023 |
| Treatment outcomes of advanced digestive well-differentiated grade 3 NETs L de Mestier, A Lamarca, J Hernando, W Zandee, T Alonso-Gordoa, ... Endocrine-Related Cancer 28 (8), 549-561, 2021 | 30 | 2021 |
| Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin J Capdevila, J Hernando, A Teulé, C Lopez, R Garcia-Carbonero, ... Nature Communications 14 (1), 2973, 2023 | 26 | 2023 |
| What is the status of immunotherapy in thyroid neoplasms? A Garcia-Alvarez, J Hernando, A Carmona-Alonso, J Capdevila Frontiers in endocrinology 13, 929091, 2022 | 25 | 2022 |
| LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the … R Salazar, S Tafuto, M Krogh, A Teule, R Garcia-Carbonero, HJ Klumpen, ... Annals of Oncology 33, S1412, 2022 | 22 | 2022 |
| Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial E Grande, C Rodriguez-Antona, C López, T Alonso-Gordoa, M Benavent, ... The Oncologist 26 (11), 941-949, 2021 | 22 | 2021 |
| Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy JLM de Nova, J Hernando, MS Núñez, GTV Benítez, EMT Ibáñez, ... World Journal of Gastroenterology 28 (13), 1304, 2022 | 19 | 2022 |
| Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase … J Capdevila, N Fazio, C Lopez, A Teule, JW Valle, S Tafuto, A Custodio, ... Annals of Oncology 29, viii467, 2018 | 18 | 2018 |
| 496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 … MCR Martinez, JC Castillon, V Alonso, P Jimenez-Fonseca, A Teule, ... Annals of Oncology 33, S769, 2022 | 17 | 2022 |
| Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela, M Antonio, C Font, ... Clinical and Translational Oncology 19, 386-395, 2017 | 17 | 2017 |
| Clinical and translational challenges in thyroid cancer J Hernando, J Ros, A Arroyo, J Capdevila Current Medicinal Chemistry 27 (29), 4806-4822, 2020 | 14 | 2020 |
| Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer … J Aparicio, AC Virgili Manrique, J Capdevila, F Muñoz Boza, P Galván, ... Clinical and Translational Oncology 24 (11), 2155-2165, 2022 | 13 | 2022 |
